IL323849A - VEGF antagonists for use in the treatment of diabetic macular edema - Google Patents
VEGF antagonists for use in the treatment of diabetic macular edemaInfo
- Publication number
- IL323849A IL323849A IL323849A IL32384925A IL323849A IL 323849 A IL323849 A IL 323849A IL 323849 A IL323849 A IL 323849A IL 32384925 A IL32384925 A IL 32384925A IL 323849 A IL323849 A IL 323849A
- Authority
- IL
- Israel
- Prior art keywords
- vegf antagonist
- patient
- weeks
- disease activity
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
277333/ VEGF ANTAGONISTS FOR USE IN TREATING DIABETIC MACULAR EDEMA FIELD OF THE INVENTION The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to treating diabetic macular edema with less frequent dosing than currently approved treatment regimens.
BACKGROUND OF THE INVENTION Diabetes mellitus (DM) is the most common endocrine disease in developed countries, with prevalence estimates ranging between 2 to 5% of the world population. Diabetic retinopathy (DR) and diabetic macular edema (DME) are common microvascular complications in patients with diabetes and may have a debilitating impact on visual acuity (VA), eventually leading to blindness. DME is a frequent manifestation of DR (Riordan-Eva, 2004, Eye (Lond). 2004, 18:1161-8) and is the major cause of visual loss in patients with DR.
For anti-VEGF agents like ranibizumab or aflibercept a favorable benefit risk ratio was demonstrated with superior efficacy versus the previous standard of care (laser photocoagulation) in large Phase 3 programs that consequently led to their approval for the treatment of DME. Anti-VEGF treatment led to clinically relevant improvements of BCVA, reduction of fluid accumulation and decreased severity of diabetic retinopathy.
The current treatment options for patients with DME are: laser photocoagulation, intravitreal (IVT) corticosteroids, IVT corticosteroid implants, or IVT anti-VEGF therapeutic. Due to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Corticosteroids are used as a second line treatment and focal / grid laser photocoagulation remains a therapeutic option, but with a lower expected benefit compared with steroid and anti-VEGF therapy.
Despite the treatment success of existing anti-VEGFs, there remains a need for further treatment options to improve response rate and/or reduce resource use and injection frequency in patients with DME (Mitchell et al., 2011, Ophthalmology 118(4):615-25; Smiddy, 2011, Ophthalmology 118(9):1827–33; Lang et al., 2013, Ophthalmology 120(10):2004-12; Virgili et al., 2014, Br J Ophthalmol 98(4):421-2; Agarwal et al., 2015, Curr Diab Rep. 15(10):75).
Claims (43)
1. A method for treating diabetic macular edema (DME) in a patient, the method comprising:a) administering to the patient five individual doses of a VEGF antagonist at 6- week intervals; andb) administering to the patient an additional dose of the VEGF antagonist once every 8 weeks (q8w regimen) or once every 12 weeks (ql2w regimen) thereafter.
2. The method of claim 1, further comprising assessing the patient for DME disease activity before or after administering every q8w or ql2w dose.
3. The method of claim 2, wherein if worsening of DME disease activity is identified after a ql2w dose, the patient is switched to a q8w regimen, wherein the additional doses are administered once every 8 weeks instead of once every 12 weeks.
4. The method of claim 3, wherein the worsening of DME disease activity is a loss of letters in best corrected visual acuity (BCVA), increased central subfield thickness (CST), and/or increased fluid accumulation compared to any previous assessment.
5. The method of claim 2, wherein at week 72 after the first dose was administered, the ql2w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments.
6. The method of claim 2 or 3, wherein at week 72 after the first dose was administered, the q8w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments.
7. The method of any one of claims 3-6, wherein disease activity is assessed based on identifying dynamic changes in best corrected visual acuity (BCVA), central subfield thickness (CST), and/or intraretinal fluid status.
8. The method of any one of claims 1-7, wherein the patient is a human. WO 2019/175727 PCT/IB2019/051899
9. The method of any one of claims 1-8, wherein the anti-VEGF antagonist comprises the sequence of SEQ ID NO: 3.
10. The method of any one of claims 1-9, wherein the VEGF antagonist is administered by intravitreal injection.
11. The method of any one of claims 1-10, wherein the concentration of the VEGF antagonist is about 60, 70, 80, 90, 100, 110, or 120 mg/ml.
12. A method for treating DME comprising administering to a patient five individual doses of a VEGF antagonist at 6-week intervals, followed by additional doses every 8 weeks (q8w regimen), wherein the VEGF antagonist is anti-VEGF antibody that comprises the variable light chain sequence of SEQ ID NO: 1 and the variable heavy chain sequence of SEQ ID NO: 2.
13. The method of claim 12, further comprising assessing the patient’s DME disease activity before or after administering every q8w dose.
14. The method of claim 13, wherein if DME disease activity is improved relative to the previous assessment, the patient is switched to a ql2w regimen, wherein the additional doses are administered once every 12 weeks instead of once every 8 weeks.
15. The method of claim 14, wherein at week 72 after the first dose was administered, the ql2w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments.
16. The method of claim 15, wherein at week 72 after the first dose was administered, the q8w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments.
17. The method of any one of claims 12-16, wherein disease activity is assessed based on identifying dynamic changes in best corrected visual acuity (BCVA), central subfield thickness (CST), and/or intraretinal fluid status.
18. The method of any one of claims 12-17, wherein the patient is a human. WO 2019/175727 PCT/IB2019/051899
19. The method of any one of claims 12-18, wherein the anti-VEGF antagonist is an antibody that comprises the sequence of SEQ ID NO: 3.
20. The method of any one of claims 12-19, wherein the VEGF antagonist is administered by intravitreal injection.
21. The method of any one of claims 12-20, wherein the concentration of the VEGF antagonist is about 60, 70, 80, 90, 100, 110, or 120 mg/ml.
22. A VEGF antagonist for use in a method of treating diabetic macular edema (DME) in a patient, wherein the VEGF antagonist is administered to the patient:a) in five individual doses at 6-week intervals; andb) as an additional dose once every 8 weeks (q8w regimen) or once every 12 weeks (ql2w regimen) thereafter.
23. The VEGF antagonist for use according to claim 22, wherein the method further comprises assessing the patient for DME disease activity before or after administering every q8w or ql2w dose.
24. The VEGF antagonist for use according to claim 23, wherein if worsening of DME disease activity is identified after a ql2w dose, the patient is switched to a q8w regimen, wherein the additional doses are administered once every 8 weeks instead of once every 12 weeks.
25. The VEGF antagonist for use according to claim 24, wherein the worsening of DME disease activity is a loss of letters in best corrected visual acuity (BCVA), increased central subfield thickness (CST), and/or increased fluid accumulation compared to any previous assessment.
26. The VEGF antagonist for use according to claim 24, wherein at week 72 after the first dose of the VEGF antagonist is administered, the q 12w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments. WO 2019/175727 PCT/IB2019/051899
27. The VEGF antagonist for use according to claim 23 or 24, wherein at week 72 after the first dose of the VEGF antagonist was administered, the q8w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments.
28. The VEGF antagonist for use according to any one of claims 23-27, wherein disease activity is assessed based on identifying dynamic changes in best corrected visual acuity (BCVA), central subfield thickness (CST), and/or intraretinal fluid status.
29. The VEGF antagonist for use according to any one of claims 22-28, wherein the patient is a human.
30. The VEGF antagonist for use according to any one of claims 22-29, wherein the anti-VEGF antagonist is brolucizumab.
31. The VEGF antagonist for use according to any one of claims 22-30, wherein the VEGF antagonist is administered by intravitreal injection.
32. The VEGF antagonist for use according to any one of claims 22-31, wherein the concentration of the VEGF antagonist is about 60, 70, 80, 90, 100, 110, or 120 mg/ml.
33. A VEGF antagonist for use in a method of treating diabetic macular edema (DME) in a patient, wherein the VEGF antagonist is first provided in a loading phase, during which the patient receives five individual doses of the VEGF antagonist at 6-week intervals, and then the VEGF antagonist is provided in a maintenance phase, during which the patient receives an additional dose of the VEGF antagonist once every 8 weeks (q8w regimen) or once every 12 weeks (ql2w regimen).
34. The VEGF antagonist for use according to claim 33, wherein the method further comprises assessing the patient for DME disease activity before or after administering every q8w or ql2w dose. WO 2019/175727 PCT/IB2019/051899
35. The VEGF antagonist for use according to claim 34, wherein if worsening of DME disease activity is identified after a ql2w dose, the patient is switched to a q8w regimen, wherein the additional doses are administered once every 8 weeks instead of once every 12 weeks.
36. The VEGF antagonist for use according to claim 35, wherein the worsening of DME disease activity is a loss of letters in best corrected visual acuity (BCVA), increased central subfield thickness (CST), and/or increased fluid accumulation compared to any previous assessment.
37. The VEGF antagonist for use according to claim 34, wherein at week 72 after the first dose of the VEGF antagonist is administered, the ql2w treatment interval is extended by weeks if the patient’s DME disease activity is consistent over the previous two assessments.
38. The VEGF antagonist for use according to claim 33 or 34, wherein at week 72 after the first dose of the VEGF antagonist was administered, the q8w treatment interval is extended by 4 weeks if the patient’s DME disease activity is consistent over the previous two assessments.
39. The VEGF antagonist for use according to any one of claims 34-38, wherein disease activity is assessed based on identifying dynamic changes in best corrected visual acuity (BCVA), central subfield thickness (CST), and/or intraretinal fluid status.
40. The VEGF antagonist for use according to any one of claims 33-39, wherein the patient is a human.
41. The VEGF antagonist for use according to any one of claims 33-40, wherein the anti- VEGF antagonist is brolucizumab.
42. The VEGF antagonist for use according to any one of claims 33-41, wherein the VEGF antagonist is administered by intravitreal injection.
43. The VEGF antagonist for use according to any one of claims 33-42, wherein the concentration of the VEGF antagonist is about 60, 70, 80, 90, 100, 110, or 120 mg/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643887P | 2018-03-16 | 2018-03-16 | |
| US201962805344P | 2019-02-14 | 2019-02-14 | |
| PCT/IB2019/051899 WO2019175727A1 (en) | 2018-03-16 | 2019-03-08 | Methods for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323849A true IL323849A (en) | 2025-12-01 |
Family
ID=66049363
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277333A IL277333B2 (en) | 2018-03-16 | 2019-03-08 | Vegf antagonists for use in treating diabetic macular edema |
| IL323849A IL323849A (en) | 2018-03-16 | 2025-10-09 | VEGF antagonists for use in the treatment of diabetic macular edema |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277333A IL277333B2 (en) | 2018-03-16 | 2019-03-08 | Vegf antagonists for use in treating diabetic macular edema |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210017266A1 (en) |
| EP (1) | EP3765083A1 (en) |
| JP (3) | JP6938796B2 (en) |
| KR (2) | KR20260036043A (en) |
| CN (1) | CN111867631A (en) |
| AU (2) | AU2019235577B2 (en) |
| CA (1) | CA3091096A1 (en) |
| IL (2) | IL277333B2 (en) |
| MX (1) | MX2020009140A (en) |
| TW (1) | TWI727279B (en) |
| WO (1) | WO2019175727A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (en) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Antibodies that bind to human protein tyrosine phosphatase beta (HPTP-beta) and their uses |
| KR20180005753A (en) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Stable and soluble antibodies inhibiting vegf |
| RU2653753C1 (en) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| PL2307458T3 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| MX363351B (en) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Methods for treating vascular leak syndrome and cancer. |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| TWI806150B (en) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| KR20190130608A (en) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | Compositions and Methods for Immune Oncology |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| MX2020009140A (en) * | 2018-03-16 | 2020-09-28 | Novartis Ag | Methods for treating ocular diseases. |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF |
| CN113194993A (en) | 2018-12-18 | 2021-07-30 | 诺华股份有限公司 | Protein solution formulations containing high concentrations of anti-VEGF antibodies |
| PE20240329A1 (en) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | DEVICES AND METHODS FOR PRECISION DOSE ADMINISTRATION |
| AU2020347575A1 (en) | 2019-09-13 | 2022-03-17 | Novartis Ag | Methods for treating ocular diseases |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
| WO2022066788A1 (en) * | 2020-09-23 | 2022-03-31 | Genentech, Inc. | Machine learning prediction of injection frequency in patients with macular edema |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| JP2026520094A (en) | 2023-04-11 | 2026-06-22 | オキュラ セラピューティクス,インコーポレイテッド | Ophthalmic implants including axitinib polymorphic IV |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1802334E (en) | 2004-10-21 | 2012-11-28 | Genentech Inc | Method for treating intraocular neovascular diseases |
| KR20180005753A (en) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Stable and soluble antibodies inhibiting vegf |
| KR20180023015A (en) * | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | Use of a vegf antagonist to treat angiogenic eye disorders |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| TWI806150B (en) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
| JP6959912B2 (en) * | 2015-09-23 | 2021-11-05 | ジェネンテック, インコーポレイテッド | Optimized variant of anti-VEGF antibody |
| MX2020009140A (en) * | 2018-03-16 | 2020-09-28 | Novartis Ag | Methods for treating ocular diseases. |
-
2019
- 2019-03-08 MX MX2020009140A patent/MX2020009140A/en unknown
- 2019-03-08 WO PCT/IB2019/051899 patent/WO2019175727A1/en not_active Ceased
- 2019-03-08 KR KR1020267006178A patent/KR20260036043A/en active Pending
- 2019-03-08 US US16/980,679 patent/US20210017266A1/en active Pending
- 2019-03-08 CN CN201980017221.0A patent/CN111867631A/en active Pending
- 2019-03-08 EP EP19715998.1A patent/EP3765083A1/en active Pending
- 2019-03-08 CA CA3091096A patent/CA3091096A1/en active Pending
- 2019-03-08 KR KR1020207028377A patent/KR20200131839A/en not_active Ceased
- 2019-03-08 IL IL277333A patent/IL277333B2/en unknown
- 2019-03-08 JP JP2020547357A patent/JP6938796B2/en active Active
- 2019-03-08 AU AU2019235577A patent/AU2019235577B2/en active Active
- 2019-03-14 TW TW108108562A patent/TWI727279B/en active
-
2021
- 2021-09-01 JP JP2021142541A patent/JP2021191778A/en not_active Withdrawn
- 2021-12-14 AU AU2021286278A patent/AU2021286278C1/en active Active
-
2023
- 2023-12-15 JP JP2023212445A patent/JP2024042697A/en not_active Withdrawn
-
2025
- 2025-10-09 IL IL323849A patent/IL323849A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL277333A (en) | 2020-10-29 |
| JP2021509912A (en) | 2021-04-08 |
| IL277333B2 (en) | 2026-03-01 |
| JP6938796B2 (en) | 2021-09-22 |
| EP3765083A1 (en) | 2021-01-20 |
| TWI727279B (en) | 2021-05-11 |
| AU2021286278B2 (en) | 2023-09-14 |
| WO2019175727A1 (en) | 2019-09-19 |
| KR20200131839A (en) | 2020-11-24 |
| TW201945027A (en) | 2019-12-01 |
| AU2021286278A1 (en) | 2022-01-20 |
| RU2020133816A (en) | 2022-04-18 |
| RU2020133816A3 (en) | 2022-04-18 |
| KR20260036043A (en) | 2026-03-13 |
| JP2021191778A (en) | 2021-12-16 |
| AU2019235577A1 (en) | 2020-08-27 |
| AU2021286278C1 (en) | 2024-05-23 |
| MX2020009140A (en) | 2020-09-28 |
| CA3091096A1 (en) | 2019-09-19 |
| US20210017266A1 (en) | 2021-01-21 |
| AU2019235577B2 (en) | 2021-09-30 |
| CN111867631A (en) | 2020-10-30 |
| IL277333B1 (en) | 2025-11-01 |
| JP2024042697A (en) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277333B1 (en) | Vegf antagonists for use in treating diabetic macular edema | |
| Ishibashi et al. | The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema | |
| Sun et al. | Rationale and application of the protocol S anti–vascular endothelial growth factor algorithm for proliferative diabetic retinopathy | |
| Sakini et al. | Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights | |
| Mitchell et al. | The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema | |
| Abraham et al. | Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 | |
| Campochiaro et al. | Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study | |
| Ip et al. | Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy | |
| Kourlas et al. | Ranibizumab for the treatment of neovascular age-related macular degeneration: a review | |
| Ciulla et al. | Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration | |
| Frampton | Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration | |
| RU2572707C2 (en) | Ophthalmic drops with difluprednate for treating macular oedema | |
| JP6944958B2 (en) | Use of sirolimus for the treatment of exudative age-related macular degeneration with persistent edema | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| Samanta et al. | Emerging therapies in nonexudative age-related macular degeneration in 2020 | |
| Heier et al. | Intravitreal combined aflibercept+ anti–platelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial | |
| US20050043220A1 (en) | Methods and compositions for treating macular degeneration | |
| Gardner et al. | Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches | |
| Meshi et al. | Intravitreal administration of antiviral agents in silicone oil–filled human eyes | |
| Shukla et al. | Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis | |
| Abdelhakeem et al. | Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine‐based delivery applications and future trends | |
| Do | Antiangiogenic approaches to age-related macular degeneration in the future | |
| Ehmann et al. | Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab) | |
| Romero-Aroca | Is laser photocoagulation treatment currently useful in diabetic macular edema? | |
| Ibrahim et al. | Switching to aflibercept in diabetic macular edema after unsatisfactory response to other anti-vascular endothelial growth factor drugs |